Adriana Manari serves as the Director of Clinical Operation Program Excellence at Neumora, where she leverages her extensive experience in clinical trials to drive operational excellence across Phase I-III studies. With a proven track record in securing FDA approvals for three commercial drugs—Sabaxone, Vivitrol, and...
Adriana Manari serves as the Director of Clinical Operation Program Excellence at Neumora, where she leverages her extensive experience in clinical trials to drive operational excellence across Phase I-III studies. With a proven track record in securing FDA approvals for three commercial drugs—Sabaxone, Vivitrol, and Firdapse—Adriana brings a wealth of knowledge in drug development and regulatory compliance to her role. Her expertise spans diverse global markets, including the USA, Canada, the EU, and Non-EU regions, allowing her to navigate complex regulatory landscapes with ease.
In her current position, Adriana is instrumental in establishing robust processes that ensure performance, compliance, and inspection readiness throughout the clinical trial lifecycle. She adeptly oversees vendor performance, a critical aspect of maintaining quality and operational excellence. By fostering strong partnerships with the Quality department, Adriana effectively operationalizes the necessary procedures for the Quality Management System, ensuring that these protocols are seamlessly integrated into daily operations.
Adriana’s skill set is comprehensive, encompassing logistics management, financial analysis, and protocol design, which enables her to optimize resources and streamline processes across multiple projects and teams. Her keen attention to detail and analytical mindset empower her to identify potential challenges early, facilitating proactive solutions that enhance trial efficiency. As a leader, Adriana is committed to cultivating a culture of collaboration and continuous improvement, positioning Neumora at the forefront of innovative clinical research. Through her strategic vision and operational acumen, she is not only advancing Neumora’s clinical objectives but also contributing to the broader mission of delivering transformative therapies to patients in need.
